Clozapine and amisulpride in refractory schizophrenia and alcohol dependence [2]

Journal of Clinical Psychopharmacology

Volumn 27, Issue 5, 2007, Pages 514-516

  Dervaux, Alain ^a   Cazali, Joelle ^b  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b Orsay Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; GLICLAZIDE; HALOPERIDOL; OLANZAPINE;

ADULT; ALCOHOLISM; CASE REPORT; CLINICAL FEATURE; DIABETES MELLITUS; DRUG BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT OUTCOME;

ALCOHOLISM; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ADDICTIVE; BLOOD GLUCOSE; CLOZAPINE; COMORBIDITY; DIABETES MELLITUS; DIAGNOSIS, DUAL (PSYCHIATRY); DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SULPIRIDE;

EID: 34548702010     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31814cfaa9     Document Type: Letter

References (19)

1. Agelink MW, Kavuk I, Ak I. Clozapine with amisulpride for refractory schizophrenia. Am J Psychiatry. 2004;161:924-925.
2. Munro J, Matthiasson P, Osborne S, et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand. 2004;110:292-298.
3. Zink M, Knopf U, Henn FA, et al. Combination of clozapine and amisulpride in treatmentresistant schizophrenia - case reports and review of the literature. Pharmacopsychiatry. 2004;37:26-31.
4. Buckley P, Thomson P, Way L, et al. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. Am J Psychiatry. 1994;151:385-389.
5. Green AI, Zimmet SV, Strous RD, et al. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry. 1999;6:287-296.
6. Drake RE, Xie H, McHugo GJ, et al. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull. 2000;26:441-449.
7. Green AI. Schizophrenia and comorbid substance use disorder: effects of antipsychotics. J Clin Psychiatry. 2005;66(suppl 6):21-26.
8. Green AI, Burgess ES, Dawson R, et al. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res. 2003;60:81-85.
9. Brunette MF, Drake RE, Xie H, et al. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull. 2006;32:637-643.
10. Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006;354:472-482.
11. Petrakis IL, Nich C, Ralevski E. Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull. 2006;32:644-654.
12. Ries RK. Co-occurring alcohol use and mental disorders. J Clin Psychopharmacol. 2006;26:S30-S36.
13. Petrakis IL, O'Malley S, Rounsaville B, et al. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology. 2004;172:291-297.
14. Mueser KT, Noordsy DL, Fox L, et al. Disulfiram treatment for alcoholism in severe mental illness. Am J Addict. 2003;12:242-252.
15. Bergemann N, Kress KR, Frick A, et al. Amisulpride has no effect on plasma clozapine concentrations. J Clin Psychopharmacol. 2005;25:494-497.
16. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand. 2002;106:323-330.
17. Stahl SM. Acta Antipsychotic polypharmacy: evidence based or eminence based? Acta Psychiatr Scand. 2002;106:321-322.
18. Nordstrom AL, Farde L, Nyberg S, et al. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry. 1995;152:1444-1449.
19. Martinot JL, Paillere-Martinot ML, Poirier MF, et al. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology. 1996;124: 154-158.